Loading...
XNYS
ARMP
Market cap184mUSD
Jul 08, Last price  
5.10USD
1D
-3.95%
1Q
-55.77%
Jan 2017
-91.72%
Name

Armata Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNYS:ARMP chart
P/E
—
P/S
37.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.16%
Rev. gr., 5y
42.90%
Revenues
5m
-5.22%
9,652,0006,874,0009,864,00010,332,0008,718,00012,171,000664,000325,000409,000475,000260,000115,00000823,0004,474,0005,508,0004,529,0005,174,0004,904,000
Net income
-174m
L+818.79%
-14,257,000-19,198,000-33,990,000-16,127,000-20,720,0007,948,000-1,110,000-64,583,00023,109,000-516,000-18,838,000-12,838,000-12,110,000-19,479,000-22,181,000-23,155,000-36,917,000-69,045,000-18,916,000-173,799,000
CFO
-26m
L-31.39%
-11,230,000-15,523,000-16,391,000-11,636,000-13,882,000-10,305,000-4,281,000-7,448,000-12,572,000-9,781,000-10,589,000-9,192,000-9,382,000-15,582,000-18,270,000-23,575,000-32,481,000-47,423,000-37,551,000-25,763,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
URL
https://www.armatapharma.com/
IPO date
May 20, 1994
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT